1
项与 AAV-AAT基因疗法(Weill Cornell Medicine) 相关的临床试验Gene Therapy for Alpha-1 Antitrypsin Deficiency
This is a study of gene therapy to treat alpha-1 antitrypsin deficiency. This study aims to treat AAT deficiency with a single administration of AAV8hAAT(AVL), a gene therapy that codes for an oxidation resistant form of the AAT protein, which if safe and if efficacious, will protect the lung on a persistent basis. We hope to learn the safety/toxicity and initial evidence of efficacy of intravenous delivery of this gene therapy to alpha 1-antitrypsin (AAT) deficient individuals.
100 项与 AAV-AAT基因疗法(Weill Cornell Medicine) 相关的临床结果
100 项与 AAV-AAT基因疗法(Weill Cornell Medicine) 相关的转化医学
100 项与 AAV-AAT基因疗法(Weill Cornell Medicine) 相关的专利(医药)
100 项与 AAV-AAT基因疗法(Weill Cornell Medicine) 相关的药物交易